Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/14—Blood; Artificial blood
  • A61K35/16—Blood plasma; Blood serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• compositions of IVIG and KH proteins for modulating lymphocytes and treating hepatitis B virus are provided.
• the invention relates to the isolation and purification of blood plasma, products derived therefrom, and methods of modifying levels of immune cells and related proteins in peripheral blood and organs of a treated individual.
• antibody-based therapies that use human antibodies have low toxicity and high specificity.
• the high specificity means that the antibody targets only the disease-causing microorganism that causes disease without affecting the host's endogenous organisms, therefore minimizing adverse reactions and the chance of the development of resistant organisms.
• This also means, however, that more than one antibody preparation may be required to target micro-organisms with high antigenic variation.
• Combination plasma products containing antibodies specific for a variety of diseases and afflictions, as well as therapies for administering the same, are therefore desired for addressing a range of diseases while minimizing damage to healthy cells.
• IVIG Intravenous immunoglobin
• IVIG is a blood product generally administered intravenously. IVIG is administered to patients with immunodeficiencies and its benefits for secondary ailments related to immunodeficiencies has made it an increasingly appealing first or second line treatment.
• lymphocytes are any of three types of immune cells including: (1) natural killer cells (NK cells, which function in cell-mediated, cytotoxic innate immunity), (2) T cells (for cell- mediated, cytotoxic adaptive immunity), and (3) B cells (for humoral, antibody-driven adaptive immunity).
• NK cells natural killer cells
• T cells for cell- mediated, cytotoxic adaptive immunity
• B cells for humoral, antibody-driven adaptive immunity
• Antibodies are produced by the B-cells and plasma cells after exposure to antigens. They can be either immunoglobin G (IgG), IgA, IgM, IgE, or IgD, but in the case of hyper-immunes, IgG are the antibodies of interest.
• IgG consists of four polypeptide chains, two pairs of polypeptide chains, two pairs of heavy and light chains in a Y-shaped arrangement. The top ends of the IgG molecule, Fab or antibody binding region, are created from one heavy and one light chain, forming the antigen binding site.
• This fragment variable (Fv) region contains various amino acid combinations, which makes each antibody unique.
• purified IVIG intravenous hyperimmune products contain human IgG protein, of which at least 96% is IgG containing specific antibodies against the specific antigen.
• IgG protein of which at least 96% is IgG containing specific antibodies against the specific antigen.
• Products regulating the percentages of B and T cells to target specific ailments and disease are also desirable.
• the invention relates to isolated purified human immunoglobulin plasma products, methods of their manufacture and their use in treating diseases and infections such as hepatitis B virus.
• the purified human immunoglobulin plasma products are useful in treating a variety of chronic and acute, hereditary and acquired diseases by regulating the levels of immune cells and their related proteins in the treated subject.
• various purified blood plasma products are used to treat viral infections such as HBV by modifying lymphocyte proliferation in an individual.
• Certain embodiments of the invention include the regulation of B and T cell levels in the peripheral blood and organs of a treated individual through prophylactic or therapeutic administration of purified blood plasma products.
• Other embodiments include the regulation of granulocyte and macrophage levels in the peripheral blood and organs of a treated individual through prophylactic or therapeutic administration of purified blood plasma products.
• a purified protein complex is obtained by purifying intravenous immunoglobulin G (IVIG) from human plasma fraction II+III paste.
• FIG. 73 In addition to the main component of immunoglobulin, analysis of the protein complex has shown the product to contain the following proteins: 120/E19 IGHV4-31, IGHG1 44kDa, 191/H18 IGHV4 31, IGHG1 32kDa, IGHG1 putative uncharacterized protein, DKFZp686Gl 1190, and KH proteins 33-37.
• FIG 75 The combination of KH proteins 33-37 with a concentration of 30% has been found to very effective against viruses such as H1N1, H5N1, foot and mouth disease, and to stop hepatitis B viral DNA replication.
• a purified protein complex is obtained by purifying hepatitis B immune globulin (HBIG) from human plasma fraction II+III of donors having high antibody levels of the hepatitis B surface antigen.
• FIG. 74 In addition to immunoglobulin proteins, HBIG contains the protein TF serotransferrin (sequence no. 197/H24). This complex contains KH proteins 22-37 and has been found to be effective in stopping hepatitis B viral DNA replication.
• a purified protein complex is formulated to combat the scarcity of the hepatitis B antibody. FIGs 77-78.
• This purified protein complex is a combination of 80% purified normal immunoglobulin and 20% purified hepatitis B immune globulin containing high levels of hepatitis B antibodies. In this embodiment both of the products have a concentration by ultra filtration of at least 30%.
• the purified protein complex of this embodiment contains proteins designated as KH22-37 and KH51. Additional information regarding KH designated proteins is included herein.
• a method of manufacture for a purified protein complex comprises: following manufacturing protocol to separately manufacture normal immunoglobulin and hepatitis B antibody up to the step of obtaining non-sterile final bulk for both products, taking 80% normal immunoglobulin non-sterile final bulk and mixing with 20% hepatitis B antibody non- sterile final bulk, and performing sterile filtration for filling the final product.
• FIG 77 The manufacturing protocol to separately manufacture normal immunoglobulin and hepatitis B antibody up to the step of obtaining non-sterile final bulk for both products, taking 80% normal immunoglobulin non-sterile final bulk and mixing with 20% hepatitis B antibody non- sterile final bulk, and performing sterile filtration for filling the final product.
• the method of manufacture for a purified protein complex comprises: taking 80% of normal immunoglobulin fraction II+III and 20% hepatitis B antibody fraction II+III, and dissolving the fractions together in a process tank for production of the normal immunoglobulin until the final product is filled.
• FIG 78 the method of manufacture for a purified protein complex
• Embodiments of the invention include purified protein complexes containing various proteins having unique characteristics useful in treating infection and disease.
• a "KH" designation has been assigned to certain proteins contained in the purified protein complexes.
• cytokinesis protein 4 os homo 02
• cytokinesis protein 4 os homo 77
• cytokinesis protein 4 os homo 65
• cytokinesis protein 4 os homo 35
• cytokinesis protein 4 os homo 37
• cytokinesis protein 4 os homo 96
• cytokinesis protein 4 os homo 20
• cytokinesis protein 4 os homo 20
• sv l gi
• sv l gi
• sv l gi
• IPI00023006 alpha cardiac muscle 1 os homo P GO:00062 ATP catabolic process
• IPI00023006 alpha cardiac muscle 1 os homo P GO:00069 muscle contraction
• IPI00023006 alpha cardiac muscle 1 os homo C GO:00426 actomyosin, actin part
• IPI00023006 alpha cardiac muscle 1 os homo F GO:00055 ATP binding
• IPI00023006 alpha cardiac muscle 1 os homo C GO:00017 stress fiber
• IPI00023006 alpha cardiac muscle 1 os homo F GO:00168 ATPase activity
• IPI00023006 alpha cardiac muscle 1 os homo C GO:00444 nucleoplasm part
• IPI00023006 alpha cardiac muscle 1 os homo P GO:00096 response to virus
• IPI00023006 alpha cardiac muscle 1 os homo P GO:00600 heart contraction
• IPI00023006 alpha cardiac muscle 1 os homo F GO:00198 enzyme binding
• IPI00023006 alpha cardiac muscle 1 os homo C GO:00164 myosin complex
• IPI00930226 cytoplasmic 2 os homo sapiens P GO:00098 tissue development
• IPI00930226 cytoplasmic 2 os homo sapiens P GO:00030 muscle system process
• IPI00930226 cytoplasmic 2 os homo sapiens c GO:00300 sarcomere
• IPI00930226 cytoplasmic 2 os homo sapiens P GO:00302 myofibril assembly
• IPI00930226 cytoplasmic 2 os homo sapiens P GO:00442 cellular metabolic process
• IPI00930226 cytoplasmic 2 os homo sapiens P GO:00485 organ development
• cytoplasmic 2 os homo sapiens C GO:00444 nucleoplasm part
• IPI00930226 cytoplasmic 2 os homo sapiens P GO:00080 blood circulation
• IPI00930226 cytoplasmic 2 os homo sapiens F GO:00198 enzyme binding
• VATQTCQITP AEGPWTAQY DCLGCVHPIS TQSPDLEPIL RHGIQYFNNN TQHSSLFMLN 180 EVKRAQRQW AGLNFRITYS IVQTNCSKEN FLFLTPDCKS LWNGDTGECT DNAYIDIQLR 240 IASFSQNCDI YPGKDFVQPP TKICVGCPRD IPTNSPELEE TLTHTITKLN AENNATFYFK 300 IDNVKKARVQ AVAGKKYFID FVARETTCSK ESNEELTESC ETKKLGQSLD CNAEVYWPW 360 EKKIYPTVNC QPLGMISLMK RPPGFSPFRS SRIGEIKEET TSHLRSCEYK GRPPKAGAEP 420 ASEREVS 427
• VATQTCQITP AEGPWTAQY DCLGCVHPIS TQSPDLEPIL RHGIQYFNNN TQHSSLFMLN 180 EVKRAQRQW AGLNFRMTYS IVQTNCSKEN FLFLTPDCKS LWNGDTGECT DNAYIDIQLR 240 IASFSQNCDI YPGKDFVQPP TKICVGCPRD IPTNSPELEE TLTHTITKLN AENNATFYFK 300 IDNVKKARVQ WAGKKYFID FVARETTCSK ESNEELTESC ETKKLGQSLD CNAEVYWPW 360 EKKIYPTVNC QPLGMISLMK RPPGFSPFRS SRIGEIKEET TSHLRSCEYK GRPPKAGAEP 420 ASEREVS 427 ⁇ Sequence Protein Sequence
• VATQTCQITP AEGPWTAQY DCLGCVHPIS TQSPDLEPIL RHGIQYFNNN TQHSSLFMLN 180 EVKRAQRQW AGLNFRMTYS IVQTNCSKEN FLFLTPDCKS L NGDTGECT DNAYIDIQLR 240 IASFSQNCDI YPGKDFVQPP TKICVGCPRD IPTNSPELEE TLTHTITKLN AENNATFYFK 300 IDNVKKARVQ WAGKKYFID FVARETTCSK ESNEELTESC ETKKLGQSLD CNAEVYWPW 360 EKKIYPTVNC QPLGMISLMK RPPGFSPFRS SRIGEIKEET TSHLRSCEYK GRPPKAGAEP 420 ASEREVS 427
• IPVWLTLKF TMHLFKLKDS WCFLPWMLFI SWTSHHIRDG IRHGLWICPF GKTSPLPFWL 180 Q0VDI3.1 YVIITSSLPH ICSFVMYLTG TRQMMSSKHG VRIDV 215
• ARLSQRFPKA EFAEVSKLVT DLTKVHTECC HGDLLECADD RADLAKYICE NQDSISSKLK 300 ECCEKPLLEK SHCIAEVEND EMPADLPSLA ADFVESKDVC KNYAEAKDVF LGMFLYEYAR 360 RHPDYSWLL LRLAKTYETT LEKCCAAADP HECYAKVFDE FKPLVEEPQN LIKQNCELFE 420 QLGEYKFQNA LLVRYTKKVP QVSTPTLVEV SRNLGKVGSK CCKHPEAKRM PCAEDYLSW 480 LNQLCVLHEK TPVSDRVTKC CTESLVNRRP CFSALEVDET YVPKEFNAET FTFHADICTL 540 SEKERQIKKQ TALVELVKHK PKATKEQLKA VMDDFAAFVE KCCKADDKET CFAEEGKKLV 600 AASQAALGL 609
• RVDQLKSDQS RLDSELKNMQ DMVEDYRNKY EDEINKRTNA ENEFVTIKKD VDGAYMTKVD 300 LQAKLDNLQQ EIDFLTALYQ AELSQMQTQI SETNVILSMD NNRSLDLDSI IAEVKAQYED 360 IAQKSKAEAE SLYQSKYEEL QITAGRHGDS VRNSKIEISE LNRVIQRLRS EIDNVKKQIS 420 NLQQSISDAE QRGENALKDA KNKLNDLEDA LQQAKEDLAR LLRDYQELMN TKLALDLEIA 480 TYRTLLEGEE SRMSGECAPN VSVSVSTSHT TISGGGSRGG GGGGYGSGGS SYGSGGGSYG 540 SGGGGGGGGGRG SYGSGGSSYG SGGGSYGSGG GGGGHGSYGS GSSSGGYRGG SGGGGGGSSG 600 GRGSGGGSSG GSIGGRGSSS GGV
• ARLSQRFPKA EFAEVSKLVT DLTKVHTECC HGDLLECADD RADLAKYICE NQDSISSKLK 300 ECCEKPLLEK SHCIAEVEND EMPADLPSLA ADFVESKDVC KNYAEAKDVF LGMFLYEYAR 360 RHPDYSWLL LRLAKTYETT LEKCCAAADP HECYAKVFDE FKPLVEEPQN LIKQNCELFE 420 QLGEYKFQNA LLVRYTKKVP QVSTPTLVEV SRNLGKVGSK CCKHPEAKRM PCAEDYLSW 480 LNQLCVLHEK TPVSDRVTKC CTESLVNRRP CFSALEVDET YVPKEFNAET FTFHADICTL 540 SEKERQIKKQ TALVELVKHK PKATKEQLKA VMDDFAAFVE KCCKADDKET CFAEEGKKLV 600 AASQAALGL 609
• VIDFNCTTSS VSSALANTKD SPVLIDFFED TERYRKQANK ALEKYKEEND DFASFRVDRI 180 P04196.1 ERVARVRGGE GTGYFVDFSV RNCPRHHFPR HPNVFGFCRA DLFYDVEALD LESPKNLVIN 240

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Virology (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Cell Biology (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Hematology (AREA)
• Biotechnology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Communicable Diseases (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Oncology (AREA)
• Biomedical Technology (AREA)
• Developmental Biology & Embryology (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Epidemiology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=54699755

Family Applications (1)

Country Status (10)

Cited By (3)

Families Citing this family (1)

Citations (6)

Family Cites Families (3)

• 2015
  • 2015-05-28 ES ES15799654T patent/ES2878043T3/es active Active
  • 2015-05-28 EP EP15799654.7A patent/EP3148574B1/en not_active Revoked
  • 2015-05-28 CN CN201580041532.2A patent/CN107106664A/zh active Pending
  • 2015-05-28 MX MX2016015574A patent/MX2016015574A/es unknown
  • 2015-05-28 RU RU2016151761A patent/RU2016151761A/ru not_active Application Discontinuation
  • 2015-05-28 BR BR112016027818A patent/BR112016027818A2/pt not_active Application Discontinuation
  • 2015-05-28 JP JP2017515008A patent/JP2017525752A/ja active Pending
  • 2015-05-28 AU AU2015266997A patent/AU2015266997A1/en not_active Abandoned
  • 2015-05-28 WO PCT/US2015/032807 patent/WO2015184050A1/en not_active Ceased
  • 2015-05-28 CA CA2949994A patent/CA2949994A1/en active Pending

Patent Citations (7)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events